Product Description
Mechanisms of Action: mTOR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Sarcoma|Osteosarcoma|Bone Cancer|Soft Tissue Cancer
Phase 2: Myeloid Leukemia|Myelodysplastic Syndrome|Lymphoma|Myelofibrosis|Prostate Cancer|Sarcoma|Oncology Unspecified|Liposarcoma|Leiomyosarcoma|Osteosarcoma|Endometrial Cancer|Non-Small-Cell Lung Cancer|Breast Cancer
Phase 1: Non-Small-Cell Lung Cancer|Sarcoma|Heart Cancer|Ovarian Cancer|Glioblastoma|Lymphoma|Breast Cancer|Oncology Unspecified|Endometrial Cancer|Multiple Myeloma|Oncology Solid Tumor Unspecified|Glioma|Gliosarcoma|Prostate Cancer|Colorectal Cancer|Primary Central Nervous System Lymphoma|Hepatic Insufficiency|Fallopian Tube Cancer|Liver Failure|Peritoneal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
IoNIR-002 | N/A |
Not yet recruiting |
Coronary Artery Disease|Coronary Stenosis |
2025-09-01 |
|
CHAMPIONSHIP | N/A |
Not yet recruiting |
Peripheral Arterial Disease |
2025-08-30 |
|
IonMAN | N/A |
Recruiting |
Non-ST Elevated Myocardial Infarction|Coronary Stenosis|Coronary Disease |
2023-12-01 |
|
EluNIR-005 | N/A |
Completed |
Coronary Stenosis|Myocardial Ischemia |
2021-11-02 |